Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
about
CSAR 2014: A Benchmark Exercise Using Unpublished Data from Pharma.Role of the active-site solvent in the thermodynamics of factor Xa ligand binding.Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approachCSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions.Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.
P2860
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
description
article
@en
im Juli 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2006
@uk
name
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
@en
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
@nl
type
label
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
@en
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
@nl
prefLabel
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
@en
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
@nl
P2093
P1476
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
@en
P2093
Andrew M. Mason
Caroline Whitworth
Champa Patel
Charlotte Mitchell
Chuen Chan
Claudine Haslam
Cynthia L. Kurtis
David Brown
Gary R. Manchee
Gita P. Shah
P304
P356
10.1016/J.BMCL.2006.04.053
P407
P577
2006-07-01T00:00:00Z